ISA Pharmaceuticals is dedicated to fighting cancer and infectious diseases by providing novel immunotherapeutics based on its proprietary SLP® technology to activate and employ the patient's own immune system. Its most advanced product is a therapeutic product against HPV-induced lesions. The company was founded in 2004 by Aglaia Oncology Fund and has its roots in the ground-breaking research performed by the group of internationally renowned tumor immunologist Professor Kees Melief. R&D is performed in close collaboration with the Leiden University Medical Center, the Netherlands. For more information about ISA, please visit www.isa-pharma.com.